Literature DB >> 27491909

A Test in Context: Neprilysin: Function, Inhibition, and Biomarker.

Antoni Bayes-Genis1, Jaume Barallat2, A Mark Richards3.   

Abstract

Neprilysin is a zinc-dependent endopeptidase. It is ubiquitous in distribution and promiscuous in function, with >50 putative peptide substrates with varying levels of in vitro and/or in vivo evidence of functional relevance. In the first part of this review, we discuss the genetic, structural, substrate, and pathophysiological aspects of neprilysin. We incorporate information provided by genetically modified models, as well as pre-clinical and clinical data from investigations of synthetic neprilysin inhibitors. We next highlight the value of neprilysin as a biotarget and weigh the clinical benefits of synthetic neprilysin inhibitors, either alone or in combination with antagonists of the renin-angiotensin system. Finally, we provide evidence about soluble neprilysin as a biomarker surrogate in patients with heart failure and identify important gaps that require further research before soluble neprilysin is used clinically. In sum, neprilysin is a versatile, veteran player returning yet again to center stage after an eventful career spanning >40 years.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  amyloid-beta peptides; angiotensin receptor-neprilysin inhibitor; endopeptidases; heart failure; natriuretic peptides; renin–angiotensin system

Mesh:

Substances:

Year:  2016        PMID: 27491909     DOI: 10.1016/j.jacc.2016.04.060

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  74 in total

1.  Metabolic effects of sacubitril/valsartan: are they relevant in clinical practice?

Authors:  Rafael de la Espriella-Juan; Juan Sanchis; Antoni Bayés-Genís; Julio Núñez
Journal:  Cardiovasc Diagn Ther       Date:  2018-08

Review 2.  Genetic variation and function of the HIV-1 Tat protein.

Authors:  Cassandra Spector; Anthony R Mele; Brian Wigdahl; Michael R Nonnemacher
Journal:  Med Microbiol Immunol       Date:  2019-03-05       Impact factor: 3.402

3.  Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas à cause du BNP?

Authors:  Naveen L Pereira; Viral K Desai; Allan S Jaffe
Journal:  Eur J Heart Fail       Date:  2019-03-04       Impact factor: 15.534

4.  A novel chemical inducer of Streptococcus quorum sensing acts by inhibiting the pheromone-degrading endopeptidase PepO.

Authors:  Tiara G Pérez Morales; Kiira Ratia; Duo-Sheng Wang; Artemis Gogos; Laura Bloem; Tom G Driver; Michael J Federle
Journal:  J Biol Chem       Date:  2017-12-04       Impact factor: 5.157

Review 5.  Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction.

Authors:  Miguel Pinilla-Vera; Virginia S Hahn; David A Kass
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

6.  Renal Denervation to Treat Heart Failure.

Authors:  Thomas E Sharp; David J Lefer
Journal:  Annu Rev Physiol       Date:  2020-10-19       Impact factor: 19.318

Review 7.  Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions.

Authors:  Lloyd D Fricker; Elyssa B Margolis; Ivone Gomes; Lakshmi A Devi
Journal:  Mol Pharmacol       Date:  2020-06-02       Impact factor: 4.436

8.  ARNIs: balancing "the good and the bad" of neuroendocrine response to HF.

Authors:  Roberto Ferrari; J Cardoso; M C Fonseca; C Aguiar; J I Moreira; A Fucili; C Rapezzi
Journal:  Clin Res Cardiol       Date:  2019-09-17       Impact factor: 5.460

9.  Neprilysin Deficiency Is Associated With Expansion of Islet β-Cell Mass in High Fat-Fed Mice.

Authors:  Jacqueline H Parilla; Rebecca L Hull; Sakeneh Zraika
Journal:  J Histochem Cytochem       Date:  2018-03-19       Impact factor: 2.479

10.  Neprilysin levels at the acute phase of ST-elevation myocardial infarction.

Authors:  Hugo Bernelin; Nathan Mewton; Salim Si-Mohamed; Pierre Croisille; Gilles Rioufol; Eric Bonnefoy-Cudraz; Philippe Douek; Nathalie Dufay; Camille Amaz; Claire Jossan; Michel Ovize; Thomas Bochaton
Journal:  Clin Cardiol       Date:  2018-12-10       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.